By InvitationNot Applicable

A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

United States400 participantsStarted 2025-08-31

Plain-language summary

This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Received any amount of A2 Bio GT product on a previous A2 Bio interventional study
✓. Able to provide written informed consent for this long-term follow-up study
✓. Able to comply with study requirements

Long-term safety of previous A2 Bio GT treatment

Timeframe: 15 years post treatment with A2 Bio GT product

NCT IDNCT06885424

SponsorA2 Biotherapeutics Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2030-03-31